AOC1

The dosage should be determined based on a combination of factors such as the patient's age, physical condition and severity of the condition.

No oral formulation has been developed and can only be administered by injection or intravenous drip.

Mild adverse reactions such as drowsiness, headache, and nausea may occur, and in severe cases, allergic reactions and elevated blood pressure may occur.

The storage temperature is usually -20°C to avoid repeated freezing and thawing and exposure to light.

Efficacy evaluation needs to be carried out according to the pathophysiological characteristics and treatment criteria of different diseases.

Large-scale clinical research and economic evaluation are needed, as well as publicity and science popularization.

AOC1 can promote the protection and repair of cardiovascular system and nervous system by regulating the level of angiotensin (Ang II), and inhibit tumor growth and deterioration.

Reproducibility needs to be enhanced through multi-center clinical trials and product quality monitoring.

The possibility of interaction needs to be assessed on a patient-specific basis.

It needs to be evaluated according to different formulations and modes of administration.

It needs to be proven safe and effective in tightly controlled clinical trials and then submitted to drug regulators.

Long-term treatment options need to be evaluated according to the characteristics and treatment criteria of different diseases.

Substitutability and advantages of different diseases need to be evaluated according to their characteristics and treatment criteria.

No large-scale clinical studies have been conducted, and further confirmation of its potential safety and efficacy is needed.

Recombinant AOC1 may play a role in the treatment of cancer, cardiovascular disease and neurodegenerative diseases.

The production process usually includes gene cloning, transfection, expression, purification and other steps.